Spero Therapeutics, Inc.
SPRO
$2.26
$0.2411.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -95.61% | 174.51% | -59.60% | 39.15% | -36.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.61% | 174.51% | -59.60% | 39.15% | -36.61% |
| Cost of Revenue | -78.62% | -194.61% | -68.00% | -55.02% | -21.50% |
| Gross Profit | 65.71% | 896.67% | 76.45% | 126.00% | 4.13% |
| SG&A Expenses | -28.39% | -39.06% | -19.70% | 6.24% | 15.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.84% | -72.44% | -60.17% | -43.43% | -12.13% |
| Operating Income | 48.21% | 250.64% | 60.58% | 87.61% | -4.11% |
| Income Before Tax | 48.05% | 254.29% | 57.66% | 90.48% | -9.45% |
| Income Tax Expenses | -- | -10.00% | -- | -- | -- |
| Earnings from Continuing Operations | 48.05% | 250.90% | 56.95% | 90.48% | -9.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.05% | 250.90% | 56.95% | 90.48% | -9.45% |
| EBIT | 48.21% | 250.64% | 60.58% | 87.61% | -4.11% |
| EBITDA | -- | 250.64% | 60.58% | 87.62% | -4.79% |
| EPS Basic | 49.80% | 246.92% | 58.59% | 90.85% | -5.79% |
| Normalized Basic EPS | 49.13% | 256.90% | 62.51% | 91.30% | -4.46% |
| EPS Diluted | 49.80% | 239.47% | 58.59% | 90.85% | -5.79% |
| Normalized Diluted EPS | 49.13% | 248.05% | 62.51% | 91.30% | -4.46% |
| Average Basic Shares Outstanding | 3.44% | 2.72% | 3.98% | 3.83% | 3.46% |
| Average Diluted Shares Outstanding | 3.44% | 8.86% | 3.98% | 3.83% | 3.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |